RELATIVE PROGRESSION-FREE SURVIVAL OVER TIME OF NOVEL TRIPLET REGIMENS FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Betts, K. [1 ]
Chen, C. [2 ]
Zichlin, M. [1 ]
Brun, A. [2 ]
Signorovitch, J. [1 ]
Makenbaeva, D. [2 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Bristol Myers Squibb Inc, Plainsboro, NJ USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1300
引用
收藏
页码：533 / 533
页数：1
相关论文
共 50 条
  • [31] Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study
    Prabhala, Rao
    Samur, Mehmet Kemal
    Talluri, Srikanth
    Stekla, Megan
    Yenumula, Chaitanya
    Lopez, Michael A.
    Derebail, Sanika
    Potluri, Lakshmi B.
    Wang, Angela
    Katiki, Aishwarya
    Vangala, Sahan D.
    Haas, Eric
    Buonopane, Michael J.
    Heubeck, Alexander T.
    Fulciniti, Mariateresa
    Szalat, Raphael
    Lazo-Kallanian, Suzan
    Hong, Kevin
    Peluso, Teresa
    Daley, John
    Biyukov, Tsvetan
    Oriol, Albert
    Pierceall, William E.
    Richardson, Paul G.
    Anderson, Kenneth C.
    Thakurta, Anjan
    Avet-Loiseau, Herve
    Munshi, Nikhil C.
    BLOOD, 2019, 134
  • [32] Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data
    Li, Shuo
    Meng, Xiang-Yu
    Maman, Souraka Tapara Dramani
    Xiao, Yong-Nong
    Li, Sheng
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [33] Full Dose of Lenalidomide for 12 Months Followed by a Lower Maintenance Dose Improves Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma.
    Dimopoulos, Meletios A.
    Hussein, Mohamad
    Swern, Arlene S.
    Weber, Donna
    BLOOD, 2009, 114 (22) : 1122 - 1122
  • [34] The use of novel agents in the treatment of relapsed and refractory multiple myeloma
    Laubach, J. P.
    Mahindra, A.
    Mitsiades, C. S.
    Schlossman, R. L.
    Munshi, N. C.
    Ghobrial, I. M.
    Carreau, N.
    Hideshima, T.
    Anderson, K. C.
    Richardson, P. G.
    LEUKEMIA, 2009, 23 (12) : 2222 - 2232
  • [35] Treatment of relapsed and refractory multiple myeloma in the era of novel agents
    van de Donk, Niels W. C. J.
    Lokhorst, Henk M.
    Dimopoulos, Meletios
    Cavo, Michele
    Morgan, Gareth
    Einsele, Hermann
    Kropff, Martin
    Schey, Steve
    Avet-Loiseau, Herve
    Ludwig, Heinz
    Goldschmidt, Hartmut
    Sonneveld, Pieter
    Johnsen, Hans E.
    Blade, Joan
    San-Miguel, Jesus F.
    Palumbo, Antonio
    CANCER TREATMENT REVIEWS, 2011, 37 (04) : 266 - 283
  • [36] Novel treatment approaches for patients with relapsed and refractory multiple myeloma
    Sinha R.
    Lonial S.
    Current Treatment Options in Oncology, 2006, 7 (3) : 246 - 257
  • [37] The use of novel agents in the treatment of relapsed and refractory multiple myeloma
    J P Laubach
    A Mahindra
    C S Mitsiades
    R L Schlossman
    N C Munshi
    I M Ghobrial
    N Carreau
    T Hideshima
    K C Anderson
    P G Richardson
    Leukemia, 2009, 23 : 2222 - 2232
  • [38] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA
    Amin, A.
    Taylor, R.
    Alonso, A.
    Schwenke, C.
    Gaudig, M.
    Gaugris, S.
    Welten, H.
    Erhardt, W.
    Roberts, G.
    O'Leary, M.
    Wasserman, M.
    HAEMATOLOGICA, 2014, 99 : 591 - 591
  • [39] Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma
    Yang, Hongbo
    Roy, Anuja
    Yang, Chelsey
    McDonald, Evangeline
    Krishna, Arun
    Kuriakose, Emil T.
    Globe, Denise
    Siegel, David
    Jagannath, Sundar
    BLOOD, 2015, 126 (23)
  • [40] PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN RELAPSED-REFRACTORY MANTLE CELL LYMPHOMA
    Amin, A.
    Taylor, R.
    Alonso, A.
    Schwenke, C.
    Gaudig, M.
    Gaugris, S.
    Welten, H.
    Erhardt, W.
    Roberts, G.
    O'Leary, M.
    Wasserman, M.
    HAEMATOLOGICA, 2014, 99 : 147 - 148
12345